Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App

Carole H. Sudre[1,2,3] , Benjamin Murray[3] , Thomas Varsavsky[3], Mark S. Graham[3], Rose S. Penfold[4], Ruth C. Bowyer[5], Joan Capdevila Pujol[5], Kerstin Klaser[3], Michela Antonelli[3], Liane S. Canas[3], Erika Molteni[3], Marc Modat[3], M. Jorge Cardoso[3], Anna May[5], Sajaysurya Ganesh[5], Richard Davies[5], Long H Nguyen[6], David A. Drew[6], Christina M. Astley[7], Amit D. Joshi[6], Jordi Merino[8,9,10], Neli Tsereteli[11], Tove Fall[12], Maria F. Gomez[11], Emma L. Duncan[4], Cristina Menni[4], Frances M.K. Williams[4], Paul W. Franks[4,11], Andrew T. Chan[6], Jonathan Wolf[5], Sebastien Ourselin[3]א, Tim Spector[4]א, Claire J. Steves[4]א*

MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences, University College London, WC1E 7HB London
Centre for Medical Image Computing, Department of Computer Science, University College London
School of Biomedical Engineering & Imaging Sciences, King's College London, SE1 7EU, London UK
Department of Twin Research and Genetic Epidemiology, King's College London, Westminster Bridge Road, SE17EH London, UK
Zoe Global Limited,164 Westminster Bridge Road, London SE1 7RW, UK
Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, MA, USA
Division of Endocrinology & Computational Epidemiology, Boston Children's Hospital, MA, USA
8Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA.
9Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.
10Department of Medicine, Harvard Medical School, Boston, MA, USA.
11 Lund University Diabetes Centre, Department of Clinical Sciences, Malmö, Sweden
12 Molecular epidemiology, Department of Medical Sciences, Uppsala University, SE-751 85 Uppsala Sweden

Corresponding author: Claire J. Steves – Claire.j.steves@kcl.ac.uk

Reports of "Long-COVID", are rising but little is known about prevalence, risk factors, or whether it is possible to predict a protracted course early in the disease. We analysed data from 4182 incident cases of COVID-19 who logged their symptoms prospectively in the COVID Symptom Study app. 558 (13.3%) had symptoms lasting >28 days, 189 (4.5%) for >8 weeks and 95 (2.3%) for >12 weeks. Long-COVID was characterised by symptoms of fatigue,

headache, dyspnoea and anosmia and was more likely with increasing age, BMI and female

sex. Experiencing more than five symptoms during the first week of illness was associated

with Long-COVID, OR=3.53 [2.76;4.50]. A simple model to distinguish between short and long-

COVID at 7 days, which gained a ROC-AUC of 76%, was replicated in an independent sample

of 2472 antibody positive individuals. This model could be used to identify individuals for

clinical trials to reduce long-term symptoms and target education and rehabilitation services.

COVID-19 can manifest a wide severity spectrum from asymptomatic to fatal forms [1]. A further

source of heterogeneity is the duration of symptoms after the acute stage which could have

considerable impact due to the huge scale of the pandemic. Hospitalised patients are well

recognised to have lasting dyspnoea and fatigue in particular [2], yet such patients constitute the

'tip of the iceberg' of symptomatic SARS CoV2 disease [3]. Few studies capture symptoms

prospectively in the general population to ascertain with accuracy the duration of illness and

the prevalence of long-lasting symptoms.

Here we report a prospective observational cohort study of COVID-19 symptoms in a subset of

4182 users of the COVID Symptom Study app meeting inclusion criteria (see online methods) [4,5].

Briefly, the subset comprised individuals who had tested positive for SARS-CoV2 by PCR swab

testing who logged as "feeling physically normal" before the start of illness (up to 14 days

before testing) so that we could determine onset. We compare cases of long (reporting

symptoms lasting more than 28 days, LC28) and short duration (reporting symptoms lasting less

than 10 days, short-COVID). Our previous findings that clusters of symptoms predicted the

need for acute care [6] led us to hypothesize that persistent symptomatology in COVID-19 (Long-

COVID) is associated with a particular symptom pattern early in the disease which could be

used to predict who might be affected. In particular, dyspnoea has been shown to be a

significant predictor of long-term symptoms in an unselected population[7].

Figure 1 shows the duration of symptoms reported in COVID+ cases (orange) over-laid on age,

sex and BMI matched negative testing symptomatic controls (blue), depicting lines for the

definitions of short-COVID, LC28 and LC56 (symptoms for more than 56 days) used in this study.

The duration of COVID-19 symptoms followed an approximately log-normal distribution (sigma

= 0.97, location =0.78, scale = 10.07), with an overall median symptom duration of 11 days

(IQR[6;19]).

73
74   Figure 1. a) Distribution of duration of symptoms in COVID-19 – The coloured bars indicate the limits to define
75   short, LC28 and LC56. b) OR and 95% CI of LC28 with each successive decile compared to 20-30-year-olds
76

77
78
79
Of the 4182 COVID-19 swab positive users, 558 (13.3%) met the LC28 definition with a median

duration of 41 days (IQR[33,63] of whom 189 (4.5%) met LC-56, and 95 (2.3%) LC94. In contrast

1591 (38.0%) had short disease duration (median 6, IQR[4-8]). The proportion with LC28 were

comparable in all three separate countries (GB 13.3%, USA 16.1%, Sweden 12.1% p=0.35) and

for LC56 (GB 4.7%, USA 5.5%, Sweden 2.5% p=0.07).

Table 1 summarises the descriptive characteristics of the study population overall and

stratifying by symptom/disease duration. Age was significantly associated with Long-COVID

(LC28) rising from 9.9% in 18-49 year olds to 21.9% in those aged >=70 (p < 0.0005), with a clear

escalation in OR by age decile (Figure 1b), although females aged 50-60 had the highest odds.

(ST2). Individuals with Long-COVID were more likely to have required hospital assessment in the

acute period. LC28 disproportionately affected women (14.9%) compared to men (9.5%),

although this sex effect was not significant in the older age-group. Long-COVID affected all

socio-economic groups (assessed using Index of Multiple Deprivation), (Supplementary Figure

2).   Asthma was the only/unique pre-existing condition providing significant association with

long-COVID-19 (OR = 2.14 [1.55-2.96]).

96
97
98   Table 1. Characteristics of COVID-19 by duration of symptoms.
99

	Overall	Short	LC28 (including LC56)	LC56
Number	4182	1591	558	189
GB/SE/US	3491 / 473 / 218	1365 / 139 / 87	466/57/35	165/12/12
Male (%)	28.5	32.7	20.3***	16.9*
Age (years)	42.8 (13.4)	40.1 (13.6)	48.9 (12.7)***	50.9 (12.5)***
Age group	2627/1195/96	1122/331/38	259/262/24	69/96/11

Obese (%)	26.3	23.8	27.6*	26.5
BMI	27.3 (5.9)	26.8 (5.7)	27.5 (5.7)	27.5 (5.8)
Asthma (%)	10.0	7.7	15.8***	18.0***
Lung (%)	13.6	12.8	16.5**	15.9
Diabetes (%)	2.9	3.0	3.9	5.8*
Heart (%)	1.9	1.7	3.2**	4.8**
Kidney (%)	0.6	0.5	0.9	0.5
IMD (average decile)	6.4 (2.7)	6.3 (2.7)	6.7 (2.8)	6.6 (2.9)
IMD quintilesℵ	158 / 194 /830/363 /1653	64/75/334/132/634	23/23/86/49/240	10/9/26/18/88
Visit to hospital (%)	13.9	7.0	31.5***	43.9***
Number of symptoms	5.9 (2.83)	5.0(2.7)	6.9 (2.9)***	7.0 (3.1)***

100 * indicates p <0.1 ** <0.05 ***<0.01 when comparing to short covid. Comparison are performed with respect to
101 the "short duration" group. Oneway ANOVA test are performed for continuous variables and chi square tests are
102 performed when comparing proportions.
103 ℵ IMD information is only available for app users from the UK who have entered a complete post code
104 Acronyms: GB – Great Britain / SE – Sweden / US – United States / IMD – Index of multiple deprivation
105

Fatigue (97.7%) and headache (91.2%) were the most reported symptoms in those with Long-

COVID, followed by anosmia and lower respiratory symptoms. Notably, while fatigue was

reported continuously, other symptoms such as headache are reported intermittently (Figure 2,

supplementary Table s1). To get better insight into the reported symptoms, we additionally

analysed free text responses which were more common in Long-COVID cases (81%) than Short-

COVID (45%). Cardiac symptoms (palpitations, tachycardia) were over-represented in the LC28

group (6.1%) compared to in short-COVID (0.5%) (p<0.0005) as were concentration or memory

issues (4.1% vs 0.2%) (p<0.0005), tinnitus and earache (3.6% vs 0.2% p<0.0005) and peripheral

neuropathy symptoms (pins and needles and numbness) (2% vs 0.5%) (p=0.004). Most of these

symptoms were reported for the first time 3-4 weeks post symptom onset.

We examined whether there were different types of symptomatology within Long-COVID. We

found two main patterns: those reporting exclusively fatigue, headache and upper respiratory

complaints (shortness of breath, sore throat, persistent cough and loss of smell) and those with

multi-system complaints including ongoing fever and gastroenterological symptoms

(Supplementary figure 3). In the individuals with long duration (LC28), ongoing fever OR 2.16

[1.50 - 3.13] and skipped meals OR 2.52 [1.74; 3.65] were strong predictors of a subsequent

hospital visit. Details of the frequency of symptoms persisting beyond 28 and 56 days after

disease onset are provided in Supplementary table 3.

125
126

127
Figure 2 : Symptoms by duration. For each symptom (ordered from top to bottom by increasing frequency of
occurrence) the median duration of report is presented by the total (hollowed) bar height, with associated
interquartile range represented by the black line, for the short, LC28 and LC56 durations. The filled bars represent
the number of times a report has been given. This highlights the differences in the symptoms in terms of their
intermittence throughout the course of the disease. (Abbreviations DE – delirium, AP – Abdominal Pain, HV –
Hoarse Voice, DI – Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP – Unusual Muscle pains, FV – Fever, ST –
Sore Throat, PC – Persistent Cough, LOS – Loss of smell, SOB – Shortness of breath, HA – Headache, FA – Fatigue)

Individuals with long-COVID were more likely to report relapses (16.0%), compared to those not

reporting long symptom duration (8.4%) (p<0.0005). In comparison, in the matched group of

SARS-CoV2 negative tested individuals, a new bout of illness was reported in 11.5% of cases.

Relapse in the context of long-COVID was longer than in the matched controls (median = 9 [5-

18] vs 6 [4-10] days).

We explored how to predict risk of Long-COVID from data available early in the disease course.

Individuals reporting more than 5 symptoms in the first week (the median number reported)

were significantly more likely to go on to experience LC28, (OR=3.95 [3.10;5.04]). This strongest

risk factor was predictive in both sexes and all age groups (supplementary Figures 4, a-e).

When analysed individually after adjusting for age and sex, every symptom in isolation was

positively predictive of longer illness duration. The five symptoms experienced during the first

week most predictive of Long-COVID were: fatigue OR=2.83 [2.09; 3.83], headache OR=2.62

[2.04;3.37], dyspnoea OR=2.36 [1.91;2.91], hoarse voice OR=2.33 [1.88 - 2.90] and myalgia

OR=2.22 [1.80;2.73] (Figure 3). Similar patterns were observed in men and women. In adults

aged over 70, loss of smell (which is less common) was the most predictive of long-COVID

OR=7.35 [1.58 - 34.22] before fever OR=5.51 [1.75 - 17.36] and hoarse voice

OR=4.03[1.21,13.42] (Supplementary figures 4). Plotting frequency of co-occurrence of

symptoms in short-COVID versus long-COVID further illustrates the importance of early multi-

symptom involvement (Figure 3c).

159
160
161
Figure 3: Symptom correlates of long-COVID for LC28 (a) and LC56 (b) with correction for age and gender. c) Co-
occurrence network of symptom pairs with the frequency of symptom report as the size of the node and the
likelihood of symptom pair co-occurrence by the weight of the edge linking them. Edges representing a co-
occurrence of less than 10% were removed. d) – Receiver Operating Characteristic (ROC) curve of the cross-
validated full and reduced models on the PCR cohort. e)– ROC curve when training on the whole PCR cohort and
testing on the antibody-positive cohort for the full (blue) and reduced (magenta) model. Random predictive
probability is indicated in both panels as a dashed red line. (Abbreviations DE – delirium, AP – Abdominal Pain, HV
– Hoarse Voice, DI – Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP – Unusual Muscle pains, FV – Fever, ST –
Sore Throat, PC – Persistent Cough, LOS – Loss of smell, SOB – Shortness of breath, HA – Headache, FA – Fatigue)

171
We further created Random Forest Prediction models using a combination of the first week's

symptom reporting, personal characteristics and comorbidities. Using all features, the average

ROC AUC was 76.7% (SD=2.5) (Figure 3d) in the classification between short-COVID and LC28.

The strongest predictor was age (29.2 %) followed by the number of symptoms during the first

week (16.3%) and BMI (10.8%) while gender (3.7%) was ranked 6th shortly after hoarse voice

(4.1) and shortness of breath (3.8). All individual symptoms, except abdominal pain and

confusion, surpassed the comorbidity features. The ranking of feature importance was

relatively similar across specific age group models. However, in the over 70s group it appeared

that early features such as fever, loss of smell and comorbidities (especially heart and lung

disease) were important, and thus could be considered 'red flags' in older adults

(supplementary figure 6).

We simplified the prediction model to include only symptom number in the first week with age,

and sex in a logistic regression model and we obtained ROC AUC of 76.7% (SD 2.5) (Figure 3d).

When optimising the balance between false positives and false negatives, we obtained a

specificity of 73.4% (SD 9.7) and a sensitivity of 68.7% (SD 9.9).

Key predictive findings of our analysis were validated in an independent dataset of 2472

individuals who reported testing antibody positive for SARS-CoV2 from 2 weeks after symptom

onset where, again, the number of symptoms in the first week of illness was the strongest

predictor of long-COVID, OR=5.12 [95% CI 3.65; 7.19]. The simple prediction model for Long-

COVID, trained on the PCR positive cohort and including number of distinct symptoms

experienced during the first week, age, and sex was similarly predictive of LC28, with a ROC

AUC of 76.3% (SD=3.7%) (Figure 5 - b).

While this study provides important insights into the disease presentation, any generalisation

should be considered carefully. Our study was limited by being confined to app users who were

disproportionately female and under-represented those >70years which could increase or

decrease our estimate of the extent of Long-COVID respectively. Applying a weighting following

the UK population (see Supplementary Methods) the estimated proportion of people

experiencing symptomatic COVID-19 going on to suffer long-COVID were similar: 14.5%, 5.1%

and 2.2% for 4, 8- and 12-weeks duration respectively. These estimates may still be

conservative: whilst estimates could be inflated due to PCR testing in the first wave being

restricted to those more severely unwell, or if regular logging may have encouraged more

symptoms to be noticed, Long-COVID may here be underestimated if individuals with

prolonged symptoms were more likely to stop logging symptoms on the app. We had

insufficient numbers to explore risk factors for disease over 2 months and were unable to

analyse the impact of ethnicity due to incomplete data in this subset. In addition, while the list

of symptoms on the app is necessarily non-exhaustive, the analysis of the free-text responses

allowed us to highlight other symptoms present in long-COVID, such as cardiac and neurological

manifestations starting generally a few weeks after the symptom onset. With emerging

evidence of ongoing myocardial inflammation and change in neurological markers [8,9] associated

with COVID-19, this calls for specific studies of cardiac and neurological longer-term sequelae of

COVID-19.

At the population level, it is critical to quantify the burden of Long-COVID to better assess its

impact on the healthcare system and appropriately distribute resources. In our study,

prospective logging of a wide range of symptoms allowed us to conclude that the proportion of

people with symptomatic COVID-19 who experience prolonged symptoms is considerable, and

relatively stable across three countries with different cultures. Whether looking at a four-week

or an eight-week threshold for defining long duration, those experiencing Long-COVID were

consistently older, more female and were more likely to require hospital assessment than in the

group reporting symptoms for a short period of time. The multi-system nature of the initial

disease in Long-COVID was illustrated by the importance of the number of symptoms, and co-

occurrence networks showing that those going on to experience long-COVID had greater

number of concurrent symptoms, therefore supporting the need for holistic support [10]. While

asthma was not reported as a factor of risk for hospitalisation in [11], its association with Long-

COVID warrants further investigation.

We found early disease features were predictive of duration. With only three features - number

of symptoms in the first week, age and sex, a simple scoring derived from a logistic regression

was able to accurately distinguish individuals with Long-COVID from those with short duration.

Importantly, the model generalised well to the population reporting antibody testing. This

important information could feature in highly needed targeted education material for both

patients and healthcare providers. Moreover, the method could help determine at-risk groups

and could be used to target early intervention trials of treatment (for example, of

dexamethasone[12] and remdesivir [13]) and clinical service developments to support rehabilitation

in primary and specialist care [14] to alleviate Long-COVID and facilitate timely recovery.

Ethics: In the UK, the App Ethics has been approved by KCL ethics Committee REMAS ID 18210,
review reference LRS-19/20-18210 and all subscribers provided consent. In Sweden, ethics
approval for the study was provided by the central ethics committee (DNR 2020-01803).
Funding: Zoe provided in kind support for all aspects of building, running and supporting the
app and service to all users worldwide. Support for this study was provided by the NIHR-funded
Biomedical Research Centre based at GSTT NHS Foundation Trust. This work was supported by
the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for
Value Based Healthcare.
Investigators also received support from the Wellcome Trust, the MRC/BHF, Alzheimer's
Society, EU, NIHR, CDRF, and the NIHR-funded BioResource, Clinical Research Facility and BRC
based at GSTT NHS Foundation Trust in partnership with KCL. ATC was supported in this work
through a Stuart and Suzanne Steele MGH Research Scholar Award. CM is funded by the
Chronic Disease Research Foundation and by the MRC AimHy project grant. LHN, DAD, ADJ,
ADS, CG, WL are supported by the Massachusetts Consortium on Pathogen Readiness
(MassCPR) and Mark and Lisa Schwartz. JM was partially supported by the European
Commission Horizon 2020 program (H2020-MSCA-IF-2015-703787). The work performed on the
Swedish study is supported by grants from the Swedish Research Council, Swedish Heart-Lung
Foundation and the Swedish Foundation for Strategic Research (LUDC-IRC 15-0067).
Competing interests:
Zoe Global Limited co-developed the app *pro bono* for non-commercial purposes. Investigators
received support from the Wellcome Trust, the MRC/BHF, EU, NIHR, CDRF, and the NIHR-
funded BioResource, Clinical Research Facility and BRC based at GSTT NHS Foundation Trust in
partnership with KCL. RD, JW, JCP, AM and SG work for Zoe Global Limited and TDS and PWF
are consultants to Zoe Global Limited. LHN, DAD,JM, PWF and ATC previously participated as
investigators on a diet study unrelated to this work that was supported by Zoe Global Ltd.
Data and materials availability: Data used in this study is available to bona fide researchers
through UK Health Data Research using the following link

https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259

269
270

271   **References**

273   1.   Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C.
274   Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019
275   (COVID-19): A Review. *JAMA - Journal of the American Medical Association* vol. 324 782–
276   793 (2020).
2.   Sheehy, L. M. Considerations for postacute rehabilitation for survivors of COVID-19.

Journal of Medical Internet Research vol. 22 (2020).

3.   Alwan, N. A. A negative COVID-19 test does not mean recovery. *Nat. 2020 5847820*
(2020).

4.   Menni, C. *et al.* Real-time tracking of self-reported symptoms to predict potential COVID-
19. *Nat. Med.* **26**, 1037–1040 (2020).

5.   Drew, D. A. *et al.* Rapid implementation of mobile technology for real-time epidemiology
of COVID-19. *Science (80-.).* eabc0473 (2020) doi:10.1126/science.abc0473.

6.   Sudre, C. H. *et al.* Symptom clusters in Covid19: A potential clinical prediction tool from
the COVID Symptom study app. *medRxiv* 2020.06.12.20129056 (2020)
doi:10.1101/2020.06.12.20129056.

7.   Cirulli, E. T. *et al.* Long-term COVID-19 symptoms in a large unselected population.
medRxiv (2020) doi:10.1101/2020.10.07.20208702.

8.   Mitrani, R. D., Dabas, N. & Goldberger, J. J. COVID-19 cardiac injury: Implications for long-
term surveillance and outcomes in survivors. *Hear. Rhythm* (2020)
doi:10.1016/j.hrthm.2020.06.026.

9.   Padda, I., Khehra, N., Jaferi, U. & Parmar, M. S. The Neurological Complexities and
Prognosis of COVID-19. *SN Compr. Clin. Med.* (2020) doi:10.1007/s42399-020-00527-2.

10. *Living with Covid19*. https://evidence.nihr.ac.uk/themedreview/living-with-covid19/
(2020) doi:10.3310/themedreview_41169.

11. Robinson, L. B. *et al.* Title: COVID-19 severity in asthma patients: A multi-center matched
cohort study. *medRxiv* 2020.10.02.20205724 (2020) doi:10.1101/2020.10.02.20205724.

12. Mahase, E. Covid-19: Demand for dexamethasone surges as RECOVERY trial publishes
preprint. *BMJ* **369**, m2512 (2020).

13. Beigel, J. H. *et al.* Remdesivir for the Treatment of Covid-19 — Preliminary Report. *N.*
Engl. J. Med. (2020) doi:10.1056/nejmoa2007764.

14. Greenhalgh, T., Knight, M., A'Court, C., Buxton, M. & Husain, L. Management of post-
acute covid-19 in primary care. *BMJ* **370**, (2020).

15. Drew, D. A. *et al.* Rapid implementation of mobile technology for real-time epidemiology
of COVID-19. *Science (80-.).* (2020).

16. Spiel, C. *et al.* A Euclidean distance-based matching procedure for non randomized
comparison studies. *Eur. Psychol.* **13**, 180–187 (2008).

Online methods

Methods

Dataset:

Data used in this study were acquired through the COVID 19 Symptom Study app, a mobile

health application developed by Zoe Global Limited with input from physicians and scientists at

King's College London, Massachusetts General Hospital, Lund and Uppsala Universities[15]. The

app, which collects data on personal characteristics and through prospective logging of

symptoms, was launched in the UK, the US and Sweden between 24th March (UK) and 30th April

(Sweden), and rapidly reached over 4 million users. This study focuses on 4182 users who

reported testing positive to SARS-CoV2 by PCR swab test and had a disease onset between 25th

March 2020 and 30th June 2020, for whom onset date matched with date of test and duration

of symptoms could be estimated (Supplementary figure 1 presents a flowchart of study

inclusion). We repeated analyses in an independent subgroup of 2472 app users who reported

positive testing for antibodies against SARS-CoV2 more than 2 weeks after symptom onset, but

without swab test results (Supplementary Figure 1).

To understand how the relapse rate compared to a comparable population not suffering from

COVID-19, we selected an additional matched sample from all app users meeting study

inclusion criteria but testing negative by PCR swab test, choosing for each COVID+ case the

individual from the negative group with the smallest Euclidean distance based on sex, age and

BMI [16].

Definitions

Onset of disease was defined as the first day of reporting at least one symptom lasting more

than one day.

Disease end was defined as the last day of unhealthy reporting before reporting healthy for

more than one week or the last day of reporting with less than 5 symptoms before ceasing

using the app. For the participants included who ceased using the app with a cumulative

number of symptoms of less than 5, disease end was considered as the last log.

Relapse was defined as 2 or more days of symptoms within a 7-day window after one week of

healthy logging, given initial symptoms close to a positive swab test.

Long-COVID was defined as symptoms persisting for a period of more than 4 weeks (28 days

LC28), more than 8 weeks (56 days, LC56) or more than 12 weeks (LC94) between symptom

onset and end, while short duration was defined as the interval between symptom onset and

end of less than 10 days, without a subsequent relapse (Short-COVID).

Inclusion/Exclusion criteria

To be included in the subsequent analysis, users of the COVID Symptoms Study app were

selected based on the following criteria:

Inclusion criteria: Age >=18 yrs; reporting a positive SARS-CoV-2 swab test (PCR) confirming the

diagnosis of COVID-19; disease onset between 14 days before and 7 days after the test date,

and before the 30th June 2020 (to limit right censoring).

Exclusion criteria: individuals who started app reporting when already unwell; users reporting

exclusively healthy throughout the study period; users with gaps of more than 7 days after an

unhealthy report and not reporting any hospital visit (to account for gaps due to

hospitalisation). In addition, individuals reporting for less than 28 days but reporting more than

5 symptoms at their last log were excluded, as duration could not be ascertained.

Statistical testing and modelling

Data collected prospectively until 02 September were included to allow sufficient time to

ascertain duration. Univariate and multivariate logistic regression was used to assess symptoms

associated with short- and long-COVID respectively, adjusting for sex and age, using

Statsmodels v0.11.1 Python3.7. Separate models were fitted to subgroups stratified by sex and

age (18-49; 50-69; >70). For analysis of relapse, results were compared for the long-COVID

group to the whole sample using Mann Whitney U test.

We used a K-mode clustering analysis to investigate whether there was evidence of different

sub-types of long-COVID, using the kmode package v0.10.2. Number of ideal symptom clusters

was obtained via a silhouette analysis with dice distance metrics. Differences between long-

COVID and short-COVID were visualised using a co-occurrence network (networkx for

visualisation), applying a 10% threshold to remove rare edges to aid visualisation.

Finally, to create a predictive model for long-COVID, we used sklearn v0.22.2.post1 package,

training random forest classifiers with stratified repeated cross-validation (10 times, 5 folds)

with hyperparameter grid search including, as features, information available during the first

week of illness, reported comorbidities (asthma, lung disease, heart disease, kidney disease and

diabetes) and personal characteristics (BMI, age, sex). In addition to a global consideration of

the studied sample population, separate models stratified by age were also entrained using a

similar cross-validation setting (hyperparameter search and stratified sampling). After running

the cross-validation for each model structure (50 times), the feature importance was averaged

across the different repeated folds. A final simplistic model using the key personal

characteristics and number of first week symptoms was further tested.

Using only 3 features, a logistic regression model was then assessed using the same

stratification and cross-validation.

To assess performance on the test dataset (antibody positive), cross-validation was also

performed to obtain an indication of the variability in performance using models that were

trained on the whole PCR positive sample.

For the reduced logistic regression model, the score was given by the following formula:

$S = 0.259503 * NumberSymptoms \ + \ 0.055457 * Age \ -0.633310 * Sex$ where sex is

encoded as 1 – Female / 2 – Male

Matching with negative sample:

The negative cases selected for matching followed the same inclusion rules and were matched

to the positive samples using the minimum Euclidean distance between the vectors of features

created by age, BMI and sex. Sex feature was multiplied by 100 to ensure balance between

feature strength.

Rebalancing to UK population demographics

Lastly, the rebalancing with respect to the UK population was performed by reweighting the

age/sex proportions of LC28 in the studied sample by the one of the UK population based on

census data from 2018. The weighting per age group is described in the table below

	Female	Male
18-49	0.263	0.264
50-69	0.156	0.150
>=70	0.093	0.075

455   **Supplementary tables and figures**
456

Supplementary Figure 1 presents a flowchart of the study inclusion. Individuals reporting
symptoms for at most 1 day are considered for the purpose of this analysis to be asymptomatic.
We further excluded users who joined the app already unhealthy, for which the onset of
disease was not calculable. Of the remainder, we further excluded those who only reported
intermittent unhealthy report and restricted to individuals reporting prospective symptoms at
least once a week over the course of the disease. The left part of the diagram represents the
inclusion flowchart for the individuals reporting a positive swab test while the right side reflects
the inclusion pathway for individuals with antibody positive test only.
465

466
467
468

471 **Supplementary Table 1** Compares the frequency (over the whole disease course), existence in
472 the first week, duration (difference between first and last day at which a symptom is reported)
473 and number of reports of a given symptom for Short-COVID, LC28 and LC56. Symptoms are
474 ordered by overall frequency in the LC28 group. Duration and number of reports are presented
475 as median [IQR] while the frequencies are presented as percentages

	Occurrence overall			Occurrence first week			Duration			Number of reports		
	Short	L28	L56	Short	L28	L56	Short	L28	L56	Short	L28	L56
FA	76.1%	97.7%	96.8%	75.9%	89.1%	87.8%	4 [2 ; 6]	33 [25 ; 56]	73 [55.5 ; 110]	4 [2 ; 6]	31.5 [19.5 ; 54.5]	68 [39 ; 118.5]
HA	65.6%	91.2%	93.7%	65.4%	80.6%	81.5%	3 [1 ; 5]	22 [10 ; 42]	56 [22 ; 93]	2.5 [1.5 ; 4]	10 [4.5 ; 19.5]	15 [7 ; 34.5]
SOB	29.4%	70.8%	75.7%	29.2%	48.4%	51.3%	2 [1 ; 5]	24 [8 ; 45]	59 [37 ; 98]	2.5 [1.5 ; 4.5]	15 [5.5 ; 34.5]	41 [15.75 ; 80.25]
LOS	49.2%	72.0%	75.1%	49.0%	56.8%	58.2%	3 [2 ; 5]	24 [11 ; 42.75]	53 [17.5 ; 84.75]	3.5 [2 ; 5]	19.5 [9 ; 34]	35.75 [11.63 ; 68.88]
PC	40.5%	68.6%	62.4%	40.4%	57.0%	52.9%	3 [1 ; 5]	20 [7.5 ; 32]	34 [14 ; 59]	3 [1.5 ; 4.5]	11.5 [4.5 ; 22.5]	19 [7 ; 40.5]
ST	41.2%	67.0%	72.5%	41.2%	53.6%	54.0%	2 [1 ; 4]	15 [3.25 ; 33.75]	33 [4 ; 63]	2.5 [1.5 ; 4]	6 [3 ; 12]	8 [3 ; 17]
FV	36.1%	62.9%	58.7%	36.1%	50.5%	45.5%	2 [1 ; 3]	6 [2 ; 14]	11 [2 ; 51.5]	2 [1.5 ; 3]	4 [2 ; 7.75]	4.5 [2 ; 11.5]
UMP	29.2%	64.0%	64.6%	29.2%	47.5%	43.4%	2 [1 ; 4]	7 [2 ; 25]	30 [4 ; 76.75]	2.5 [1.5 ; 3.5]	5 [2 ; 11]	9.5 [3 ; 30.63]
SM	29.9%	59.5%	66.7%	29.9%	46.6%	52.4%	2 [1 ; 4]	9 [3.75 ; 20]	13 [4 ; 44]	2.5 [1.5 ; 4]	6 [3 ; 14]	8 [3.5 ; 18.88]
CP	28.2%	60.0%	63.0%	28.1%	42.5%	45.0%	2 [1 ; 4]	13 [3 ; 35]	46 [17 ; 78]	2 [1.5 ; 4]	7.5 [2.5 ; 16.5]	16.5 [7.25 ; 42]
DI	20.4%	51.1%	54.5%	20.1%	34.6%	33.3%	2 [1 ; 3]	9 [2 ; 22]	15 [2 ; 46.5]	2 [1 ; 3]	4.5 [2 ; 9]	5 [2 ; 12.25]
HV	23.0%	53.0%	61.4%	22.9%	41.4%	47.6%	2 [1 ; 4]	9 [3 ; 29]	21 [4 ; 61.5]	2.5 [1.5 ; 4]	6 [3 ; 14.5]	7.5 [3.5 ; 20.625]
AP	17.2%	44.1%	49.2%	17.0%	26.0%	22.2%	1 [1 ; 3]	7 [1 ; 23]	13 [1 ; 56]	2 [1 ; 3]	3.5 [1.5 ; 8.5]	4.5 [2 ; 9.5]
DE	11.8%	30.3%	38.6%	11.7%	19.0%	24.3%	2 [1 ; 3]	8 [1 ; 23]	14 [2 ; 56]	2 [1 ; 3.5]	3.5 [1.5 ; 9]	6.5 [2 ; 16.5]

481 Supplementary Table 2 – Odd ratio of LC28 and LC56 per decade when compared to 18-30
482 category separating male and females

	Female		Male	
	LC28	LC56	LC28	LC56
30-40	2.11 [1.38 ; 3.23]	2.19 [1.02 ; 4.73]	2.62 [1.09 ; 6.27]	4.12 [0.49 ; 34.67]
40-50	4.35 [2.9 ; 6.53]	4.14 [2.02 ; 8.52]	2.24 [0.9 ; 5.62]	3.52 [0.39 ; 31.91]

50-60	8.03 [5.37 ; 12]	8.61 [4.33 ; 17.1]	6.65 [2.8 ; 15.8]	11.49 [1.44 ; 91.29]
60-70	6.53 [4.02 ; 10.6]	7.2 [3.31 ; 15.69]	7.5 [2.98 ; 18.9]	14 [1.68 ; 116.51]
>=70	5.46 [2.51 ; 11.85]	7.71 [2.6 ; 22.83]	8.27 [2.8 ; 24.39]	18.56 [1.99 ; 173.3]

486 Supplementary Table 3 – Indication of the frequency of report of symptoms beyond 28 days
487 and beyond 56 days in the LC28 and the LC56 groups.

	Reported beyond 28 days in LC28	Reported beyond 56 days in LC56
FA	0.68	0.73
HA	0.40	0.53
SOB	0.37	0.48
LOS	0.39	0.39
PC	0.27	0.22
ST	0.27	0.27
FV	0.12	0.16
UMP	0.20	0.30
SM	0.13	0.19
CP	0.23	0.31
DI	0.15	0.20
HV	0.17	0.22
AP	0.15	0.23
DE	0.11	0.15

491 Supplementary Figure 2: Ratio of LC28 and LC56 vs short-COVID by IMD quintile

493
Supplementary Figure 3 – clustering of symptoms in the Long-COVID group indicating a
common strong higher airways component with fatigue, headache and loss of smell for both
groups and a more multi system presentation for the second group. Colouring presents the
frequency of reporting of a given symptom. Abbreviations: DE – delirium, AP – Abdominal Pain,
HV – Hoarse Voice, DI – Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP – Unusual Muscle
pains, FV – Fever, ST – Sore Throat, PC – Persistent Cough, LOS – Loss of smell, SOB – Shortness
of breath, HA – Headache, FA – Fatigue
501

502
503

504
505
506
507

Supplementary Figure 4. Odd ratios of continuing into long Covid 28 when presenting a given
symptom during the first week correcting for age and gender (if necessary) in different
subgroups female(a), male (b), 18-49 (c), 50-69 (d), >=70 (e). Abbreviations: DE – delirium, AP –
Abdominal Pain, HV – Hoarse Voice, DI – Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP
– Unusual Muscle pains, FV – Fever, ST – Sore Throat, PC – Persistent Cough, LOS – Loss of
smell, SOB – Shortness of breath, HA – Headache, FA – Fatigue

517
518   Supplementary Figure 5 – Odd ratio for the risk of developing Long Covid 28 for each
519   comorbidity or risk factors correcting for age and gender in each age group,
520

521
522

Supplementary Figure 6: Comparison of mean feature importance (proportion ranging from 0

to 1) for the cross-validated random forest models across the different age groups when

considering personal characteristics and presented symptoms during the first week of the

disease. Abbreviations - (Abbreviations DE – delirium, AP – Abdominal Pain, HV – Hoarse Voice,

DI – Diarrhoea, CP – Chest Pain, SM – skipped meals, UMP – Unusual Muscle pains, FV – Fever,

ST – Sore Throat, PC – Persistent Cough, LOS – Loss of smell, SOB – Shortness of breath, HA –

Headache, FA – Fatigue)

532

533